TOOKAD

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug TOOKAD contains one active pharmaceutical ingredient (API):

1 Padeliporfin UNII JQ72VD4XUL - PADELIPORFIN POTASSIUM

Padeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a cascade of pathophysiological events resulting in focal necrosis within a few days. Read about Padeliporfin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TOOKAD Powder for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XD07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XD Sensitizers used in photodynamic/radiation therapy
Discover more medicines within L01XD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1756807, 1756818
Country: FR	Base de données publique des médicaments	Identifier(s): 65082422
Country: IT	Agenzia del Farmaco	Identifier(s): 045774015, 045774027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1084469, 1084470
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100400647, 100400660